Neuroleptic malignant syndrome: Case report of a recurrence related to olanzapine;Sindrome neuroleptica maligna: Relato de caso com recorrencia associada ao uso de olanzapina

Arquivos de Neuro-Psiquiatria

Volumn 56, Issue 4, 1998, Pages 833-837

  Hanel, Ricardo A ^a,b   Sandmann, Marcos C ^a   Kranich, Martina ^a   De Bittencourt, Paulo R M ^a  

^a Curitiba PR Aceite: 24 Agosto 1998

^b NONE   (Brazil)

Author keywords

Bromocriptine; Chlorpromazine; Dantrolene; Haloperidol; Neuroleptic malignant syndrome; Olanzapine

Indexed keywords

BROMOCRIPTINE; CHLORPROMAZINE; CREATINE KINASE; DANTROLENE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; PIRENZEPINE;

ARTICLE; BASAL GANGLION; CLINICAL FEATURE; DIAPHORESIS; DRUG INDUCED DISEASE; DYSPHAGIA; HUMAN; INCONTINENCE; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; RECEPTOR BLOCKING; RIGIDITY; TREMOR; ADULT; CASE REPORT; MALE; RECURRENT DISEASE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; HALOPERIDOL; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PIRENZEPINE; RECURRENCE;

EID: 0032235294     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x1998000500022     Document Type: Article

References (33)

1. Delay J, Pichot P, Lemperiere T Un neuroleptique majeur non phenothiazine et non reserpinique l'haloperidol dans le traitment des psychoses Ann Med Psychol (Paris )1960,118:145-152.
2. Delay J, Deniker P Drug-induced extrapyramidal syndromes In Vinken PJ, Bruyn GW (eds). Diseases of basal ganglia. Handbook of Clinical Neurology Vol 6 Amsterdam: North Holland, 1968: 248-266.
3. Friedman JH. Neuroleptic malignant syndrome In Gilman S, Goldstein GW, Waxman SG (eds) Neurobase. 3.Ed. San Diego: Arbor, 1977.
4. Gurrera RJ, Chang SS, Romero JA A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56-62.
5. Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 1995,58:271-273
6. Sternberg DE. Neuroleptic malignant syndrome: the pendulum swings. Am J Psychiatry 1986;143 1273-1275.
7. American Psychiatry Association. Diagnostic and statistical manual for mental disorders. 4.Ed Washington, DC: American Psychiatry Association, 1994.739-742
8. Levenson JL. Neuroleptic malignant syndrome Am J Psychiatry 1985,142:1137-1145.
9. Kellam AMP. The (frequently) neuroleptic (potentially) malignant syndrome Br J Psychiatry 1990;157:169-173.
10. Gelenberg AJ, Beilinghausen B, Wojcik JD, Falk WE, Sachs GS A prospective study of neuroleptic malignant syndrome in a short term psychiatric hospital Am J Psychiatry 1988,145:517-518
11. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive patients. Am J Psychiatry 1986;143:1587-1590
12. Keck PE Jr, Pope HG Jr, McElroy SL Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987;144:1344-1346
13. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population . Am J Psychiatry 1991,148.880-882.
14. Pope HG Jr, Keck PE Jr, McElroy SL Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986,143 1227-1233.
15. Lavie CJ, Olmsted TR, Ventura HO, Lepler BJ Neuroleptic malignant syndrome: an underdiagnosed reaction to neuroleptic agents? Postgraduate Med 1986;80 171-178.
16. Lavie CJ, Ventura HO, Walker G Neuroleptic malignant syndrome: three episodes with different drugs. Southern Med J 1986;79.1571-1573.
17. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's diesease after withdrawal or alteration of dopaminergic therapy Arch Intern Med. 1991;151:794-796.
18. Freedman MD. Neuroleptic malignant syndrome and acute myocardial infarction: case report and review. Md Med J. 1997;46 357-359.
19. Pope HG Jr, Keck PE Jr, Cohen BM, Nierenberg AA. Risk Factors for neuroleptic malignant syndrome. a case-control study. Arch Gen Psychiatry 1989,46 914-918.
20. Shalev A, Hermesh H, Munita H The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry 1988,145 110-111
21. Tanii H, Taniguchi N, Niigawa H, et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia and serum creatine phosphokinase level. Brain Res 1996,16.1-2,263-270.
22. Rosebush PI, Stewatt T A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989,146 717-725
23. Adityanjee. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 1991;158:706-707.
24. Montgomery JN, Ironside JW Neuroleptic malignant syndrome in the intensive therapy unit Anaesthesia 1990,45:311-313.
25. Janati A, Webb T. Successful treatment of neuroleptic malignant syndrome with bromocriptine. Southern Med J 1986;79.1567-1571
26. Rosenberg MR, Green M Neuroleptic malignant syndrome: review of response to therapy Arch Intern Med 1989,149:1927-1931
27. Sczesni B, Brittkau S, von Baumgarten Fv, von Schroder J, Suchy I, Przuntek H. Intravenous lisuride in the treatment of neuroleptic malignant syndrome. J Clin Psychopharmacol 1991;11.185-188.
28. Addonizio G, Susman VL. ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry 1987;48:102-105.
29. Gaitini L, Fradis M, Vaida S, Krimerman S, Beny A Plasmapheresis in neuroleptic malignant syndrome. Anaesthesia 1997,52:165-168.
30. Nisijima K, Noguti M, Ishiguro T Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry 1997,41.913-914.
31. Shoop SA, Cernek PK Carbidopa/levodopa in the treatment of neuroleptic malignant syndrome. Ann Pharmacother 1997;31:119.
32. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome, are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;59:709-712
33. Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 1991,52:208-212